


What is claimed is:

1. A compound of formula (I)



or a pharmaceutically acceptable salt or prodrug thereof, wherein

--- is absent or a single bond;

X₁ is selected from the group consisting of N and CR₁;

X₂ is selected from the group consisting of N and CR₂;

X₃ is selected from the group consisting of N, NR₃, and CR₃;

X₄ is a bond or selected from the group consisting of N and CR₄;


X₅ is selected from the group consisting of N and C;

provided that at least one of X₁, X₂, X₃, and X₄ is N;

Z₁ is selected from the group consisting of O, NH, and S;

Z₂ is a bond or selected from the group consisting of NH and O;

L is selected from the group consisting of alkenylene, alkylene, alkynylene,

cycloalkylene, , -(CH₂)_mO(CH₂)_n-, and N(R_Y), wherein the left end of -(CH₂)_mO(CH₂)_n- is attached to Z₂ and the right end is attached to R₉;

m and n are each independently 0-6;

R_Y is selected from the group consisting of hydrogen and alkyl;

R₁, R₃, R₅, R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy,

carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, $(\text{CF}_3)_2(\text{HO})\text{C}-$, $-\text{NR}_\text{A}\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{S}(\text{O})_2\text{OR}_\text{A}$, $-\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{NZ}_\text{A}\text{Z}_\text{B}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{alkyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonylalkyl}$ and $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{sulfonyl}$, wherein Z_A and Z_B are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, formyl, aryl, and arylalkyl;

R_2 and R_4 are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, $(\text{CF}_3)_2(\text{HO})\text{C}-$, $-\text{NR}_\text{A}\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{S}(\text{O})_2\text{OR}_\text{A}$, $-\text{S}(\text{O})_2\text{R}_\text{B}$, $-\text{NZ}_\text{A}\text{Z}_\text{B}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{alkyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{alkylcarbonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{carbonylalkyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{sulfonyl}$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NH})-$, $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NCN})\text{NH}-$, and $(\text{NZ}_\text{A}\text{Z}_\text{B})\text{C}(=\text{NH})\text{NH}-$;

R_A is selected from the group consisting of hydrogen and alkyl;

R_B is selected from the group consisting of alkyl, aryl, and arylalkyl;

$\text{R}_{8\text{a}}$ is selected from the group consisting of hydrogen and alkyl;

$\text{R}_{8\text{b}}$ is absent when X_5 is N or $\text{R}_{8\text{b}}$ is selected from the group consisting of hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, alkylcarbonyloxy, alkylsulfonyloxy, halogen, and hydroxy when X_5 is C; and

R_9 is selected from the group consisting of hydrogen, aryl, cycloalkyl, and heterocycle.

2. The compound according to claim 1 wherein

--- is a single bond;

X_1 is CR_1 ;

X_2 is CR_2 ;

X_3 is N; and

X_4 is CR_4 .

3. The compound according to claim 2 wherein

X_5 is N;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is aryl.

4. The compound according to claim 2 wherein

X₅ is N;

R₁, R₆ and R₇ are each hydrogen;

R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;

R₅ is selected from the group consisting of hydrogen and halogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_A, Z_B, Z_C, and Z_D are independently selected from the group consisting of hydrogen and alkyl.

5. The compound according to claim 4 selected from the group consisting of

N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea;

N-[2-(3-bromophenyl)ethyl]-N'-isoquinolin-5-ylurea;

N-isoquinolin-5-yl-N'-[4-(trifluoromethyl)benzyl]urea;

N-[3-fluoro-5-(trifluoromethyl)benzyl]-N'-isoquinolin-5-ylurea;

N-(2,5-dichlorobenzyl)-N'-isoquinolin-5-ylurea;

N-(1,3-benzodioxol-5-ylmethyl)-N'-isoquinolin-5-ylurea;
 N-[2-(4-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-(3-bromobenzyl)-N'-isoquinolin-5-ylurea;
 N-[2-(3,4-dimethylphenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-[1-(4-bromophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-[4-(trifluoromethoxy)benzyl]urea;
 N-isoquinolin-5-yl-N'-(4-methylbenzyl)urea;
 N-(4-fluorobenzyl)-N'-isoquinolin-5-ylurea;
 N-[2-(3,4-dichlorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-[2-(3,5-dimethoxyphenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-(4-chlorobenzyl)-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-{2-[3-(trifluoromethyl)phenyl]ethyl}urea;
 N-[2-(2,6-dichlorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-[2-(2,3-dichlorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-[3-(trifluoromethoxy)benzyl]urea;
 N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-[2-(2,4-dichlorophenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-(3-bromo-4-fluorobenzyl)-N'-isoquinolin-5-ylurea;
 N-(3,4-dimethylbenzyl)-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-(3-phenylpropyl)urea;
 N-(3,5-dichlorobenzyl)-N'-isoquinolin-5-ylurea;
 N-(3-chloro-4-methylbenzyl)-N'-isoquinolin-5-ylurea;
 N-(3,4-dichlorobenzyl)-N'-isoquinolin-5-ylurea;
 N-(3-fluorobenzyl)-N'-isoquinolin-5-ylurea;
 N-(4-tert-butylbenzyl)-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-[2-(3-methylphenyl)ethyl]urea;
 N-isoquinolin-5-yl-N'-[2-(4-methylphenyl)ethyl]urea;
 N-[2-(2,4-dimethylphenyl)ethyl]-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-[2-(2-methylphenyl)ethyl]urea;
 N-isoquinolin-5-yl-N'-{4-[(trifluoromethyl)thio]benzyl}urea;
 N-isoquinolin-5-yl-N'-[3-(trifluoromethyl)benzyl]urea;
 N-[4-chloro-3-(trifluoromethyl)benzyl]-N'-isoquinolin-5-ylurea;

N-(3,5-dimethylbenzyl)-N'-isoquinolin-5-ylurea;
 N-(3,5-difluorobenzyl)-N'-isoquinolin-5-ylurea;
 N-(4-bromobenzyl)-N'-isoquinolin-5-ylurea;
 N-(3,5-dimethoxybenzyl)-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-(3,4,5-trimethoxybenzyl)urea;
 N-isoquinolin-5-yl-N'-[4-(methylsulfonyl)benzyl]urea;
 N-(3,4-dimethoxybenzyl)-N'-isoquinolin-5-ylurea;
 N-isoquinolin-5-yl-N'-(1-naphthylmethyl)urea;
 N-(2,4-dimethylbenzyl)-N'-isoquinolin-5-ylurea;
 N-[4-(dimethylamino)benzyl]-N'-isoquinolin-5-ylurea;
 N-(4-bromobenzyl)-N'-(3-chloroisoquinolin-5-yl)urea;
 N-[(4-cyanophenyl)methyl]-N'-isoquinolin-5-ylurea;
 N-[(4-bromophenyl)methyl]-N'-(3-methylisoquinolin-5-yl)urea;
 N-[(4-bromophenyl)methyl]-N'-(1-chloroisoquinolin-5-yl)urea;
 N-[(4-bromophenyl)methyl]-N'-(1-methylisoquinolin-5-yl)urea;
 N-isoquinolin-5-yl-N'-[(4-morpholin-4-ylphenyl)methyl]urea;
 [4-(2,6-dimethylmorpholin-4-yl)phenyl]methylamine;
 N-isoquinolin-5-yl-N'-[(4-thiomorpholin-4-ylphenyl)methyl]urea;
 methyl 5-({[(4-bromobenzyl)amino]carbonyl}amino)isoquinoline-3-carboxylate;
 methyl 5-({[(2,4-dichlorobenzyl)amino]carbonyl}amino)isoquinoline-3-carboxylate;
 N-(8-bromoisoquinolin-5-yl)-N'-(2,4-dichlorobenzyl)urea;
 N-(8-bromoisoquinolin-5-yl)-N'-(4-fluorobenzyl)urea;
 N-(8-bromoisoquinolin-5-yl)-N'-(3-fluorobenzyl)urea;
 N-[1-(4-chlorophenyl)-1-methylethyl]-N'-isoquinolin-5-ylurea;
 N-(1,1'-biphenyl-4-ylmethyl)-N'-5-isoquinolinylurea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinylurea;
 N-5-isoquinolinyl-N'-(3-methylbenzyl)urea;
 N-[4-fluoro-3-(trifluoromethyl)benzyl]-N'-5-isoquinolinylurea;
 N-(3-chloro-4-fluorobenzyl)-N'-5-isoquinolinylurea;
 N-5-isoquinolinyl-N'-[4-(1-pyrrolidinyl)benzyl]urea;
 N-[4-(1-azepanyl)benzyl]-N'-5-isoquinolinylurea;
 N-[3-fluoro-4-(1-pyrrolidinyl)benzyl]-N'-5-isoquinolinylurea;

N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-5-isoquinoliny lurea;
 N-[4-(1-azocanyl)benzyl]-N'-5-isoquinoliny lurea;
 N-benzhydryl-N'-5-isoquinoliny lurea;
 N-[(1S)-1-(4-bromophenyl)ethyl]-N'-5-isoquinoliny lurea;
 N-[(1R)-1-(4-bromophenyl)ethyl]-N'-5-isoquinoliny lurea;
 N-5-isoquinoliny l-N'-{1-[4-(trifluoromethyl)phenyl]ethyl} urea;
 (-) N-5-isoquinoliny l-N'-{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl} urea;
 (+) N-5-isoquinoliny l-N'-{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl} urea;
 N-[1-(4-tert-butylphenyl)ethyl]-N'-5-isoquinoliny lurea;
 N-{cyclopropyl[4-(trifluoromethyl)phenyl]methyl}-N'-5-isoquinoliny lurea;
 N-(3-fluorobenzyl)-N'-(3-methyl-5-isoquinoliny l) urea;
 N-(4-bromo-3-fluorobenzyl)-N'-5-isoquinoliny lurea;
 N-(3-amino-5-isoquinoliny l)-N'-[4-(1-piperidiny l)benzyl] urea;
 N-(3-amino-5-isoquinoliny l)-N'-[4-(1-azepanyl)benzyl] urea;
 N-(1,1'-biphenyl-3-ylmethyl)-N'-5-isoquinoliny lurea;
 N-5-isoquinoliny l-N'-[4-(2-pyridiny l)benzyl] urea;
 N-(4-bromo-3-fluorobenzyl)-N'-(3-methyl-5-isoquinoliny l) urea;
 N-[3-fluoro-4-(4-methyl-1-piperidiny l)benzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-(3-methyl-5-isoquinoliny l)-N'-[4-(4-methyl-1-piperidiny l)benzyl] urea;
 N-[3-fluoro-4-(1-piperidiny l)benzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-(3-methyl-5-isoquinoliny l)-N'-[4-(1-piperidiny l)benzyl] urea;
 N-[4-(1-azepanyl)benzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-(3-methyl-5-isoquinoliny l)-N'-[4-(1-pyrrolidiny l)benzyl] urea;
 N-[3-fluoro-4-(1-pyrrolidiny l)benzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-[4-(1-azocanyl)benzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-[4-(1-azocanyl)-3-fluorobenzyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-[(1S)-1-(4-bromophenyl)ethyl]-N'-(3-methyl-5-isoquinoliny l) urea;
 N-{(1S)-1-[4-(1-azepanyl)phenyl]ethyl}-N'-(3-methyl-5-isoquinoliny l) urea;
 N-benzyl-N'-(3-chloro-5-isoquinoliny l) urea;
 N-(4-bromobenzyl)-N'-(1-chloro-5-isoquinoliny l) urea;
 N-(4-cyanobenzyl)-N'-5-isoquinoliny lurea;

N-(4-bromobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(4-bromobenzyl)-N'-(1-methyl-5-isoquinoliny)urea;
 N-5-isoquinoliny-N'-[4-(4-morpholiny)benzyl]urea;
 N-[4-(2,6-dimethyl-4-morpholiny)benzyl]-N'-5-isoquinolinyurea;
 N-5-isoquinoliny-N'-[4-(4-thiomorpholiny)benzyl]urea;
 N-(4-bromobenzyl)-N'-(3-fluoro-5-isoquinoliny)urea;
 N-(3-chloro-5-isoquinoliny)-N'-[4-(4-morpholiny)benzyl]urea;
 N-[3,5-difluoro-4-(4-morpholiny)benzyl]-N'-5-isoquinolinyurea;
 N-(4-bromobenzyl)-N'-(1,3-dimethyl-5-isoquinoliny)urea;
 N-(3,4-dimethylbenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-[3,5-bis(trifluoromethyl)benzyl]-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3-amino-5-isoquinoliny)-N'-(4-bromobenzyl)urea;
 N-(3-methyl-5-isoquinoliny)-N'-[4-(trifluoromethyl)benzyl]urea;
 N-(4-tert-butylbenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(4-tert-butylbenzyl)-N'-(1,3-dimethyl-5-isoquinoliny)urea;
 N-(4-tert-butylbenzyl)-N'-(1,3-dimethyl-5-isoquinoliny)urea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-(3-methyl-5-isoquinoliny)urea;
 N-[1-(4-bromophenyl)ethyl]-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3,4-dichlorobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(2,4-dichlorobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3-chlorobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3-methyl-5-isoquinoliny)-N'-[4-(trifluoromethoxy)benzyl]urea;
 N-[2-(3,4-dichlorophenyl)ethyl]-N'-(3-methyl-5-isoquinoliny)urea;
 N-(4-ethylbenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3-methyl-5-isoquinoliny)-N'-{2-[4-(trifluoromethyl)phenyl]ethyl}urea;
 N-(3-methyl-5-isoquinoliny)-N'-{4-[(trifluoromethyl)thio]benzyl}urea;
 N-(4-chlorobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(2,4-difluorobenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-(1,3-dimethyl-5-isoquinoliny)-N'-[3-fluoro-4-(trifluoromethyl)benzyl]urea;
 N-(4-isopropylbenzyl)-N'-(3-methyl-5-isoquinoliny)urea;
 N-[4-fluoro-3-(trifluoromethyl)benzyl]-N'-(3-methyl-5-isoquinoliny)urea;
 N-(3-amino-5-isoquinoliny)-N'-{1-[4-(trifluoromethyl)phenyl]ethyl}urea;

N-(3-amino-5-isoquinoliny)-N'-[3-fluoro-4-(trifluoromethyl)benzyl]urea;
 N-(5-bromo-2-fluorobenzyl)-N'-5-isoquinolinyurea;
 N-(4-chloro-2-fluorobenzyl)-N'-5-isoquinolinyurea;
 N-(4-tert-butylbenzyl)-N'-5-isoquinolinyurea;
 N-(3,4-difluorobenzyl)-N'-5-isoquinolinyurea;
 N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}-N'-5-isoquinolinyurea;
 N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]propyl}-N'-5-isoquinolinyurea;
 N-(8-bromo-5-isoquinoliny)-N'-(2,4-dichlorobenzyl)urea;
 N-(8-bromo-5-isoquinoliny)-N'-(4-fluorobenzyl)urea;
 N-(8-bromo-5-isoquinoliny)-N'-(3-fluorobenzyl)urea;
 N-[1-(4-chlorophenyl)-1-methylethyl]-N'-5-isoquinolinyurea;
 N-(4-bromo-3-methylbenzyl)-N'-5-isoquinolinyurea;
 N-[2-fluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinyurea;
 N-(4-bromobenzyl)-N'-(3-hydroxy-5-isoquinoliny)urea;
 N-[3-bromo-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinyurea;
 N-[2,4-bis(trifluoromethyl)benzyl]-N'-5-isoquinolinyurea;
 N-[2,3-difluoro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinyurea;
 N-[2-chloro-4-(trifluoromethyl)benzyl]-N'-5-isoquinolinyurea;
 N-5-isoquinoliny-N'-{1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}urea; and
 N-[2-(4-bromophenyl)-2-hydroxyethyl]-N'-5-isoquinolinyurea.

6. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is aryl wherein said aryl is substituted with aryloxy.

7. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl substituted with aryloxy wherein said aryloxy is phenoxy optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

8. The compound according to claim 7 selected from the group consisting of N-isoquinolin-5-yl-N'-(4-phenoxybenzyl)urea; and N-isoquinolin-5-yl-N'-(3-phenoxybenzyl)urea.

9. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is aryl wherein said aryl is naphthyl.

10. The compound according to claim 9 that is N-isoquinolin-5-yl-N'-(1-naphthylmethyl)urea.

11. The compound according to claim 2 wherein
X₅ is N;
R_{8b} is absent;
Z₁ is O;
Z₂ is NH;
L is alkylene; and
R₉ is cycloalkyl.
12. The compound according to claim 2 wherein
X₅ is N;
R₁, R₆ and R₇ are each hydrogen;
R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;
R₅ is selected from the group consisting of hydrogen and halogen;
R_{8a} is hydrogen;
R_{8b} is absent;
Z₁ is O;
Z₂ is NH;
L is alkylene;
R₉ is cycloalkyl wherein said cycloalkyl is selected from the group consisting of adamantanyl, bicyclo[3.1.1]heptane, and cyclohexyl, wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl substituents; and
Z_A and Z_B are independently selected from the group consisting of hydrogen and alkyl.
13. The compound according to claim 12 selected from the group consisting of
N-(1-adamantylmethyl)-N'-5-isoquinoliny lurea;
N-(cyclohexylmethyl)-N'-5-isoquinoliny lurea;
N-[(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]-N'-5-isoquinoliny lurea;
N-[(4-tert-butylcyclohexyl)methyl]-N'-5-isoquinoliny lurea; and
N-5-isoquinoliny l-N'-{[4-(trifluoromethyl)cyclohexyl]methyl} urea.

14. The compound according to claim 2 wherein
 - X₅ is N;
 - R_{8b} is absent;
 - Z₁ is O;
 - Z₂ is NH;
 - L is alkylene; and
 - R₉ is heterocycle.

15. The compound according to claim 2 wherein
 - X₅ is N;
 - R₁, R₆ and R₇ are each hydrogen;
 - R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;
 - R₅ is selected from the group consisting of hydrogen and halogen;
 - R_{8a} is hydrogen;
 - R_{8b} is absent;
 - Z₁ is O;
 - Z₂ is NH;
 - L is alkylene;
 - R₉ is heterocycle wherein said heterocycle is pyridinyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and
 - Z_A, Z_B, Z_C, and Z_D are independently selected from the group consisting of hydrogen and alkyl.

16. The compound according to claim 15 that is N-5-isoquinolinyl-N'-{[5-(trifluoromethyl)-2-pyridinyl]methyl}urea.

17. The compound according to claim 2 wherein
X₅ is N;
Z₁ is O;
Z₂ is NH;
R_{8b} is absent; and
R₉ is hydrogen.
18. The compound according to claim 2 wherein
X₅ is N;
R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;
R_{8a} is hydrogen;
R_{8b} is absent;
Z₁ is O;
Z₂ is NH;
L is alkylene; and
R₉ is hydrogen.
19. The compound according to claim 18 selected from the group consisting of
N-hexyl-N'-isoquinolin-5-ylurea;
N-5-isoquinolinylnyl-N'-pentylurea; and
N-5-isoquinolinylnyl-N'-octylurea.
20. The compound according to claim 2 wherein
X₅ is N;
Z₁ is O;
Z₂ is NH;
L is cycloalkylene;
R_{8b} is absent; and
R₉ is aryl.
21. The compound according to claim 2 wherein
X₅ is N;

R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is cycloalkylene;

R₉ is aryl wherein said aryl is phenyl optionally optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

22. The compound according to claim 21 that is N-isoquinolin-5-yl-N'-[(trans)-2-phenylcyclopropyl]urea.

23. The compound according to claim 2 wherein

X₅ is N;

Z₁ is O;

Z₂ is a bond;

L is cycloalkylene;

R_{8b} is absent; and

R₉ is aryl.

24. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is a bond;

L is cycloalkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

25. The compound according to claim 24 that is N-5-isoquinolinyl-2-phenylcyclopropanecarboxamide.

26. The compound according to claim 2 wherein

X₅ is N;

Z₁ is O;

Z₂ is NH;

L is -(CH₂)_mO(CH₂)_n- wherein the left end is attached to Z₂ and the right end is attached to R₉;

R_{8b} is absent; and

R₉ is aryl.

27. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆, R₇, and R_{8a} are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is -(CH₂)_mO(CH₂)_n- wherein the left end is attached to Z₂ and the right end is attached to R₉;

m is 0-2;

n is 0-2;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

28. The compound according to claim 27 selected from the group consisting of N-isoquinolin-5-yl-N'-(2-phenoxyethyl)urea; and N-[(2,4-dichlorobenzyl)oxy]-N'-5-isoquinolinyurea.

29. The compound according to claim 2 wherein

X₅ is N;

Z₁ is O;

Z₂ is NH;

L is N(R_Y);

R_{8b} is absent; and

R₉ is aryl.

30. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅, R₆, R₇, and R_{8a} are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is N(R_Y);

m is 2-4;

n is 0;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl,

2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.


31. The compound according to claim 30 that is N-5-isoquinolinyl-2-[4-(trifluoromethyl)phenyl]hydrazinecarboxamide.

32. The compound according to claim 2 wherein

X₅ is N;

Z₁ is O;

Z₂ is a bond;



R_{8b} is absent; and

R₉ is aryl.

33. The compound according to claim 2 wherein

X₅ is N;


R₁, R₅, R₆, R₇, and R_{8a} are each hydrogen;

R_{8b} is absent;

R₂ is selected from the group consisting of hydrogen and alkyl;

Z₁ is O;

Z₂ is a bond;



R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano,

haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

34. The compound according to claim 33 that is selected from the group consisting of
- 4-(3,4-dichlorophenyl)-N-isoquinolin-5-ylpiperazine-1-carboxamide;
 - 4-(3-chlorophenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;
 - 4-(3,4-dimethylphenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;
 - 4-(4-chlorophenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;
 - N-5-isoquinolinyl-3-methyl-4-(4-methylphenyl)-1-piperazinecarboxamide;
 - 4-(2,3-dimethylphenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;
 - 4-(2,3-dichlorophenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;
 - 4-(3,4-dichlorophenyl)-N-(3-methyl-5-isoquinolinyl)-1-piperazinecarboxamide;
 - N-5-isoquinolinyl-4-[3-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;
 - 4-(4-bromophenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide;

35. The compound according to claim 2 wherein

X₅ is N;

R₁, R₂, R₄, R₅ and R₆ are each hydrogen;

R₇ is (CF₃)₂(HO)C-;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

36. The compound according to claim 35 that is N-(4-bromobenzyl)-N'-{6-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]isoquinolin-5-yl}urea.

37. The compound according to claim 2 wherein

X_5 is N;

Z_1 is O;

Z_2 is O;

L is alkylene;

R_{8b} is absent; and

R_9 is aryl.

38. The compound according to claim 2 wherein

X_5 is N;

R_1 , R_2 , R_4 , R_5 , R_6 , R_7 , and R_{8a} are each hydrogen;

R_{8b} is absent;

Z_1 is O;

Z_2 is O;

L is alkylene;

R_9 is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and - NZ_CZ_D ; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

39. The compound according to claim 38 selected from the group consisting of 4-(trifluoromethyl)benzyl isoquinolin-5-ylcarbamate;

2-(3-bromophenyl)ethyl isoquinolin-5-ylcarbamate;
4-cyanobenzyl isoquinolin-5-ylcarbamate;
4-methylbenzyl 5-isoquinolinylcarbamate;
4-bromobenzyl 5-isoquinolinylcarbamate;
2-(4-chlorophenyl)ethyl 5-isoquinolinylcarbamate; and
2-[2-(trifluoromethyl)phenyl]ethyl 5-isoquinolinylcarbamate.

40. The compound according to claim 2 wherein
X₅ is N;
R₁, R₂, R₄, R₅, R₆ and R₇ are each hydrogen;
Z₁ is O;
Z₂ is O;
L is alkylene;
R_{8b} is absent; and
R₉ is aryl wherein said aryl is naphthyl.
41. The compound according to claim 40 that is 1-naphthylmethyl isoquinolin-5-ylcarbamate.
42. The compound according to claim 2 wherein
X₅ is N;
R_{8b} is absent;
Z₁ is O;
Z₂ is a bond;
L is alkenylene; and
R₉ is aryl.
43. The compound according to claim 2 wherein
X₅ is N;
R₁, R₆ and R₇ are each hydrogen;
R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;

R₅ is selected from the group consisting of hydrogen and halogen;

R_{8a} is hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is a bond;

L is alkenylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_A, Z_B, Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

44. The compound according to claim 43 that is selected from the group consisting of
(2E)-N-5-isoquinolinyl-3-[4-(trifluoromethyl)phenyl]-2-butenamide;
N-5-isoquinolinyl-3-[4-(trifluoromethyl)phenyl]-3-butenamide;
(2Z)-N-5-isoquinolinyl-3-[4-(trifluoromethyl)phenyl]-2-butenamide;
(2E)-3-[3-fluoro-4-(trifluoromethyl)phenyl]-N-5-isoquinolinyl-2-butenamide;
3-[3-fluoro-4-(trifluoromethyl)phenyl]-N-5-isoquinolinyl-3-butenamide;
(2E)-N-5-isoquinolinyl-3-[4-(1-piperidinyl)phenyl]-2-butenamide;
N-5-isoquinolinyl-3-[4-(trifluoromethyl)phenyl]acrylamide;
N-5-isoquinolinyl-3-[3-(trifluoromethyl)phenyl]acrylamide;
3-(4-isopropylphenyl)-N-5-isoquinolinylacrylamide;
3-(3,4-dichlorophenyl)-N-5-isoquinolinylacrylamide;
3-(1,1'-biphenyl-4-yl)-N-5-isoquinolinylacrylamide;
3-(3-bromo-4-fluorophenyl)-N-5-isoquinolinylacrylamide;
3-(4-tert-butylphenyl)-N-5-isoquinolinylacrylamide; and
3-[3-fluoro-4-(trifluoromethyl)phenyl]-N-5-isoquinolinylacrylamide.

45. The compound according to claim 2 wherein

X₅ is C;
Z₁ is O;
Z₂ is NH;
L is alkylene; and
R₉ is heterocycle.

46. The compound according to claim 2 wherein

X₅ is C;
R₁, R₆ and R₇ are each hydrogen;

R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;

R₅ is selected from the group consisting of hydrogen and halogen;

R_{8a} is hydrogen;

R_{8b} is hydrogen;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is heterocycle wherein said heterocycle is selected from the group consisting of imidazolyl, pyridinyl, pyrrolidinyl, and thienyl, wherein the heterocycle is optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, oxo, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_A, Z_B, Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

47. The compound according to claim 46 selected from the group consisting of

2-(5-isoquinolinyl)-N-[2-(2-thienyl)ethyl]acetamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-(5-isoquinolinyl)acetamide;

2-(5-isoquinolinyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]acetamide; and

2-(5-isoquinolinyl)-N-[2-(3-pyridinyl)ethyl]acetamide.

48. The compound according to claim 2 wherein
X₅ is C;
Z₁ is O;
Z₂ is NH;
L is -(CH₂)_mO(CH₂)_n- wherein the left end is attached to Z₂ and the right end is attached to R₉; and
R₉ is hydrogen.
49. The compound according to claim 2 wherein
X₅ is C;
R₁, R₆ and R₇ are each hydrogen;
R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;
R₅ is selected from the group consisting of hydrogen and halogen;
R_{8a} is hydrogen;
R_{8b} is hydrogen;
Z₁ is O;
Z₂ is NH;
L is -(CH₂)_mO(CH₂)_n- wherein the left end is attached to Z₂ and the right end is attached to R₉;
m is 0-4;
n is 0-4;
R₉ is hydrogen; and
Z_A and Z_B are independently selected from the group consisting of hydrogen and alkyl.
50. The compound according to claim 49 that is N-(3-butoxypropyl)-2-(5-isoquinoliny)acetamide.
51. The compound according to claim 2 wherein
X₅ is C;

Z₁ is O;
Z₂ is NH;
L is alkylene; and
R₉ is aryl.

52. The compound according to claim 2 wherein

X₅ is C;

R₁, R₆, R₇, R_{8a} and R_{8b} are each hydrogen;

R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;

R₅ is selected from the group consisting of hydrogen and halogen;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_A, Z_B, Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

53. The compound according to claim 52 selected from the group consisting of

2-isoquinolin-5-yl-N-[4-(trifluoromethyl)benzyl]acetamide;

N-(4-bromobenzyl)-2-(3-methyl-5-isoquinolinyl)acetamide;

N-(4-bromobenzyl)-2-(5-isoquinolinyl)acetamide;

N-[1-(4-bromophenyl)ethyl]-2-(5-isoquinolinyl)acetamide;

N-[1-(4-bromophenyl)ethyl]-2-(3-methyl-5-isoquinolinyl)acetamide;

2-(5-isoquinolinyl)-N-[4-(trifluoromethoxy)benzyl]acetamide;

N-(4-tert-butylbenzyl)-2-(5-isoquinolinyl)acetamide;

N-[3-fluoro-4-(trifluoromethyl)benzyl]-2-(5-isoquinolinyl)acetamide;

N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}-2-(5-isoquinoliny)acetamide;
 N-{1-[3-fluoro-4-(trifluoromethyl)phenyl]propyl}-2-(5-isoquinoliny)acetamide;
 2-(3-methyl-5-isoquinoliny)-N-[4-(trifluoromethyl)benzyl]acetamide;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-2-(3-methyl-5-isoquinoliny)acetamide;
 2-(5-isoquinoliny)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}acetamide;
 N-(3,3-diphenylpropyl)-2-(5-isoquinoliny)acetamide;
 2-(5-isoquinoliny)-N-(3-phenylpropyl)acetamide;
 N-(2,2-diphenylethyl)-2-(5-isoquinoliny)acetamide;
 N-benzyl-2-(5-isoquinoliny)acetamide;
 2-(5-isoquinoliny)-N-{4-[(trifluoromethyl)thio]benzyl}acetamide;
 2-(5-isoquinoliny)-N-(2-phenylethyl)acetamide;
 N-[3-bromo-4-(trifluoromethyl)benzyl]-2-(5-isoquinoliny)acetamide;
 N-(4-bromo-3-methylbenzyl)-2-(5-isoquinoliny)acetamide;
 N-[2,4-bis(trifluoromethyl)benzyl]-2-(5-isoquinoliny)acetamide;
 N-[2-chloro-4-(trifluoromethyl)benzyl]-2-(5-isoquinoliny)acetamide;
 N-[2,3-difluoro-4-(trifluoromethyl)benzyl]-2-(5-isoquinoliny)acetamide; and
 N-[4-(1-azepanyl)-3-fluorobenzyl]-2-(5-isoquinoliny)acetamide.

54. The compound according to claim 2 wherein

X₅ is C;

R₁, R₆, and R₇ are each hydrogen;

R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;

R₅ is selected from the group consisting of hydrogen and halogen;

R_{8a} is selected from the group consisting of hydrogen and alkyl;

R_{8b} is alkyl;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano,

haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_A, Z_B, Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

55. The compound according to claim 54 selected from the group consisting of
- N-[3-fluoro-4-(trifluoromethyl)benzyl]-2-(5-isoquinolinyl)propanamide;
 - 2-(5-isoquinolinyl)-N-[4-(trifluoromethyl)benzyl]propanamide;
 - 2-(5-isoquinolinyl)-N-[3-(trifluoromethyl)benzyl]propanamide;
 - 2-(5-isoquinolinyl)-N-{4-[(trifluoromethyl)thio]benzyl}propanamide;
 - N-(4-bromobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(4-tert-butylbenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-[3-fluoro-5-(trifluoromethyl)benzyl]-2-(5-isoquinolinyl)propanamide;
 - 2-(5-isoquinolinyl)-N-[4-(trifluoromethoxy)benzyl]propanamide;
 - 2-(5-isoquinolinyl)-N-[3-(trifluoromethoxy)benzyl]propanamide;
 - N-(2,4-dimethylbenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(2,5-dimethylbenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(2,3-dichlorobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(2,4-dichlorobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(2,5-dichlorobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(3,4-dichlorobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-(3,5-dichlorobenzyl)-2-(5-isoquinolinyl)propanamide;
 - N-[4-(1-azepanyl)benzyl]-2-(5-isoquinolinyl)propanamide;
 - N-[4-(1-azepanyl)-3-fluorobenzyl]-2-(5-isoquinolinyl)propanamide;
 - N-[3-fluoro-4-(trifluoromethyl)benzyl]-2-(5-isoquinolinyl)butanamide;
 - 2-(5-isoquinolinyl)-N-[4-(trifluoromethyl)benzyl]butanamide;
 - N-(4-bromobenzyl)-2-(5-isoquinolinyl)butanamide;
 - 2-(5-isoquinolinyl)-N-{4-[(trifluoromethyl)thio]benzyl}butanamide;
 - N-[4-(1-azepanyl)-3-fluorobenzyl]-2-(5-isoquinolinyl)butanamide; and
 - 2-(5-isoquinolinyl)-2-methyl-N-{4-[(trifluoromethyl)thio]benzyl}propanamide.

56. The compound according to claim 2 wherein
X₅ is C;
R₁, R₆, and R₇ and are each hydrogen;
R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;
R₅ is selected from the group consisting of hydrogen and halogen;
R_{8a} is hydrogen;
R_{8b} is selected from the group consisting of alkoxy, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, halogen, and hydroxy;
Z₁ is O;
Z₂ is NH;
L is alkylene;
R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and
Z_A, Z_B, Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.
57. The compound according to claim 56 selected from the group consisting of
N-(4-tert-butylbenzyl)-2-hydroxy-2-(5-isoquinolinyl)acetamide;
N-(4-tert-butyl-3-fluorobenzyl)-2-hydroxy-2-(5-isoquinolinyl)acetamide;
tert-butyl 4-[(4-tert-butylbenzyl)amino]-3-(5-isoquinolinyl)-4-oxobutanoate;
2-[(4-tert-butylbenzyl)amino]-1-(5-isoquinolinyl)-2-oxoethyl acetate;
2-[(4-tert-butylbenzyl)amino]-1-(5-isoquinolinyl)-2-oxoethyl methanesulfonate;
N-(4-tert-butylbenzyl)-2-(5-isoquinolinyl)-2-methoxyacetamide; and
N-(4-tert-butylbenzyl)-2-chloro-2-(5-isoquinolinyl)acetamide.
58. The compound according to claim 2 wherein
X₅ is C;

R₁, R₆, R₇, and R₇ are each hydrogen;
R₂ and R₄ are independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, and -NZ_AZ_B;
R₅ is selected from the group consisting of hydrogen and halogen;
R_{8a} is selected from the group consisting of hydrogen and alkyl;
R_{8b} is selected from the group consisting of hydrogen, alkoxycarbonylalkyl, alkyl, and hydroxy;
Z₁ is O;
Z₂ is O;
L is alkylene;
R₉ is hydrogen; and
Z_A and Z_B are independently selected from the group consisting of hydrogen and alkyl.

59. The compound according to claim 58 selected from the group consisting of ethyl 5-isoquinolinylacetate;
ethyl 2-(5-isoquinolinyl)propanoate;
ethyl 2-(5-isoquinolinyl)butanoate;
ethyl 2-(5-isoquinolinyl)-2-methylpropanoate;
ethyl hydroxy(5-isoquinolinyl)acetate; and
4-tert-butyl 1-ethyl 2-(5-isoquinolinyl)succinate.

60. The compound according to claim 1 wherein
--- is a single bond;
X₁ is CR₁;
X₂ is CR₂;
X₃ is N; and
X₄ is N.

61. The compound according to claim 60 wherein
X₅ is N;
R_{8b} is absent;

Z₁ is O;
Z₂ is NH;
L is alkylene; and
R₉ is aryl.

62. The compound according to claim 60 wherein

X₅ is N;
R₁, R₅, R₆ and R₇ are each hydrogen;
R_{8b} is absent;
R₂ is selected from the group consisting of alkyl and halogen;
Z₁ is O;
Z₂ is NH;
L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

63. The compound according to claim 62 that is N-(3,4-dichlorobenzyl)-N'-(3-methylcinnolin-5-yl)urea.

64. The compound according to claim 1 wherein

--- is a single bond;
X₁ is CR₁;
X₂ is N;
X₃ is CR₃; and
X₄ is CR₄.

65. The compound according to claim 64 wherein
 X_5 is N;
 R_{8b} is absent;
 Z_1 is O;
 Z_2 is NH;
L is alkylene; and
 R_9 is aryl.
66. The compound according to claim 64 wherein
 X_5 is N;
 R_1 , R_3 , R_4 , R_5 , R_6 and R_7 are each hydrogen;
 R_{8b} is absent;
 Z_1 is O;
 Z_2 is NH;
L is alkylene;
 R_9 is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and $-NZ_CZ_D$; and
 Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.
67. The compound according to claim 66 selected from the group consisting
N-isoquinolin-8-yl-N'-[4-(trifluoromethyl)benzyl]urea; and
N-(4-bromobenzyl)-N'-isoquinolin-8-ylurea.
68. The compound according to claim 1 wherein
--- is absent;
 X_1 is CR_1 ;
 X_2 is CR_2 ;

X₃ is NR₃; and

X₄ is a bond.

69. The compound according to claim 68 wherein

X₅ is N;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is aryl.

70. The compound according to claim 68 wherein

X₅ is N;

R₁, R₂, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D;

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl; and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

71. The compound according to claim 70 selected from the group consisting of

N-(4-bromobenzyl)-N'-1H-indol-4-ylurea;

N-(3,4-dichlorobenzyl)-N'-1H-indol-4-ylurea;

N-1H-indol-4-yl-N'-[4-(trifluoromethyl)benzyl]urea;

N-1H-indol-4-yl-N'-[4-(trifluoromethoxy)benzyl]urea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-1H-indol-4-ylurea;
 1-(4-Chloro-3-trifluoromethyl-benzyl)-3-(1H-indol-4-yl)-urea;
 1-(4-Chloro-3-trifluoromethyl)-3-(1H-indol-4-yl)-urea; and
 N-[2-(2,4-dichlorophenyl)ethyl]-N'-1H-indol-4-ylurea.

72. The compound according to claim 68 wherein

X₅ is N;

R₁ and R₂ are each independently alkyl;

R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D;

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl; and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

73. The compound according to claim 72 that is N-(4-bromobenzyl)-N'-(2,3-dimethyl-1H-indol-4-yl)urea.

74. The compound according to claim 68 wherein

X₅ is N;

R_{8b} is absent;

Z₁ is O;

Z₂ is O;

L is alkylene; and

R₉ is aryl.

75. The compound according to claim 68 wherein

X₅ is N;

R₁, R₂, R₅, R₆ and R₇ are each hydrogen;

R₃ is selected from the group consisting of hydrogen and alkyl;

R_{8b} is absent;

Z₁ is O;

Z₂ is O;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D;

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl; and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

76. The compound according to claim 75 selected from the group consisting of

4-(trifluoromethyl)benzyl 1H-indol-4-ylcarbamate; and

4-(trifluoromethoxy)benzyl 1H-indol-4-ylcarbamate.

77. The compound according to claim 1 wherein

--- is absent;

X₁ is CR₁;

X₂ is N;

X₃ is NR₃; and

X₄ is a bond.

78. The compound according to claim 77 wherein
 X_5 is N;
 R_{8b} is absent;
 Z_1 is O;
 Z_2 is NH;
L is alkylene; and
 R_9 is aryl.
79. The compound according to claim 77 wherein
 X_5 is N;
 R_1 , R_5 , R_6 and R_7 are each hydrogen;
 R_{8b} is absent;
 Z_1 is O;
 Z_2 is NH;
L is alkylene;
 R_9 is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and $-NZ_CZ_D$; and
 Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.
80. The compound according to claim 79 selected from the group consisting of
N-(3,4-dichlorobenzyl)-N'-1H-indazol-4-ylurea;
N-1H-indazol-4-yl-N'-[4-(1-piperidinyl)benzyl]urea;
N-[3-fluoro-4-(1-piperidinyl)benzyl]-N'-1H-indazol-4-ylurea;
N-1H-indazol-4-yl-N'-[4-(1-pyrrolidinyl)benzyl]urea;
N-[3-fluoro-4-(1-pyrrolidinyl)benzyl]-N'-1H-indazol-4-ylurea;
N-[4-(1-azepanyl)benzyl]-N'-1H-indazol-4-ylurea;
N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-1H-indazol-4-ylurea;

N-(1-methyl-1H-indazol-4-yl)-N'-[4-(1-piperidiny)benzyl]urea;
 N-[3-fluoro-4-(1-piperidiny)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(1-methyl-1H-indazol-4-yl)-N'-[4-(1-pyrrolidiny)benzyl]urea;
 N-[3-fluoro-4-(1-pyrrolidiny)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(1-azepanyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 methyl 4-({[(1-naphthylmethyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;
 methyl 4-({[(1,1'-biphenyl-3-ylmethyl)amino]carbonyl}amino)-1H-indazole-1-
 carboxylate;
 methyl 4-({[(2-chlorobenzyl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;
 methyl 4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}carbonyl)amino]-1H-
 indazole-1-carboxylate;
 N-(1,1'-biphenyl-3-ylmethyl)-N'-1H-indazol-4-ylurea;
 N-(2-chlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-[2-fluoro-5-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[2-(2,4-dimethylphenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-[2-(3,4-dichlorophenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-[2-(4-methylphenyl)ethyl]urea;
 N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-azepan-1-yl-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(2-azabicyclo[2.2.1]hept-2-yl)-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-
 ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-(trifluoromethyl)benzyl]-N'-1H-indazol-4-
 ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-fluorobenzyl]-N'-1H-indazol-4-ylurea;
 N-(3-chloro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[(1S)-1-(4-bromophenyl)ethyl]-N'-1H-indazol-4-ylurea;
 N-(3-bromo-4-fluorobenzyl)-N'-1H-indazol-4-ylurea;
 N-(2,4-dimethylbenzyl)-N'-1H-indazol-4-ylurea;
 N-(4-chlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-(4-methylbenzyl)urea;

N-1H-indazol-4-yl-N'-[3-(trifluoromethoxy)benzyl]urea;
 N-(3-chloro-4-fluorobenzyl)-N'-1H-indazol-4-ylurea;
 N-(3,4-dimethylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[3-fluoro-5-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea;
 N-(2-chloro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-(2,3-dichlorobenzyl)-N'-1H-indazol-4-ylurea;
 N-1H-indazol-4-yl-N'-{4-[(trifluoromethyl)thio]benzyl}urea;
 N-1H-indazol-4-yl-N'-[3-(trifluoromethyl)benzyl]urea;
 N-(3,5-difluoro-4-azepan-1-ylbenzyl)-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorobenzyl]-N'-1H-indazol-4-ylurea;
 N-(4-chlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-chlorobenzyl]-N'-1H-indazol-4-ylurea;
 methyl 4-[(4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)benzyl)amino]carbonyl]amino]-1H-indazole-1-carboxylate;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-chlorobenzyl]-N'-1H-indazol-4-ylurea;
 N-[4-(8-azabicyclo[3.2.1]oct-8-yl)benzyl]-N'-1H-indazol-4-ylurea;
 N-(4-tert-butylbenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[3-fluoro-4-(trifluoromethyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[4-chloro-3-(trifluoromethyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(3,4-dichlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2,4-dichlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(4-ethylbenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2-chlorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(4-fluorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-(2-fluorobenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea;
 N-[1-(4-bromophenyl)ethyl]-N'-(1-methyl-1H-indazol-4-yl)urea; and
 N-(1-methyl-1H-indazol-4-yl)-N'-{4-[(trifluoromethyl)thio]benzyl}urea.

81. The compound according to claim 77 wherein

R_{8a} , R_1 , R_5 , R_6 and R_7 are each hydrogen;

R_{8b} is absent;

X_5 is N;

Z₁ is O;

Z₂ is NH;

L is alkylene wherein the alkylene is -CH₂-;

R₉ is aryl wherein said aryl is phenyl substituted with 2 substituents independently selected from the group consisting of (8-azabicyclo[3.2.1]oct-8-yl), trifluoromethyl, and -Cl;
and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

82. The compound according to claim 77 wherein

R_{8a}, R₁, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

X₅ is N;

Z₁ is O;

Z₂ is NH;

L is alkylene wherein the alkylene is -CH₂-;

R₉ is aryl wherein said aryl is 4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)phenyl; and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

83. The compound according to claim 77 wherein

R_{8a}, R₁, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

X₅ is N;

Z₁ is O;

Z₂ is NH;

L is alkylene wherein the alkylene is -CH₂-;

R₉ is aryl wherein said aryl is 2-chloro-4-(8-azabicyclo[3.2.1]oct-8-yl)phenyl; and

R₃ is selected from the group consisting of hydrogen and alkoxycarbonyl.

84. The compound according to claim 81 selected from the group consisting of

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-2-chlorobenzyl]-N'-1H-indazol-4-ylurea; and

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)benzyl]-N'-1H-indazol-4-ylurea.

85. The compound according to claim 77 wherein

X₅ is N;

R₁, R₆ and R₇ are each hydrogen;

R₅ is alkyl;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene;

R₉ is aryl wherein said aryl is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidiny, 4-methyl-1-piperidiny, pyridiny, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

86. The compound according to claim 85 selected from the group consisting of

N-(4-tert-butylbenzyl)-N'-(7-methyl-1H-indazol-4-yl)urea;

N-(7-methyl-1H-indazol-4-yl)-N'-[4-(trifluoromethyl)benzyl]urea; and

N-(7-methyl-1H-indazol-4-yl)-N'-{4-[(trifluoromethyl)thio]benzyl}urea.

87. The compound according to claim 77 wherein

X₅ is N;

R₁, R₆ and R₇ are each hydrogen;

R₅ is alkyl;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is aryl wherein said aryl is selected from the group consisting of naphthyl and phenyl.

88. The compound according to claim 87 selected from the group consisting of N-1H-indazol-4-yl-N'-(1-naphthylmethyl)urea; and N-1H-indazol-4-yl-N'-(3-phenylpropyl)urea.

89. The compound according to claim 77 wherein

X₅ is N;

R₁, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is alkylene; and

R₉ is heterocycle wherein said heterocycle is pyridinyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D.

90. The compound according to claim 89 that is N-1H-indazol-4-yl-N'-{[6-(trifluoromethyl)-3-pyridinyl]methyl}urea.

91. The compound according to claim 77 wherein


X₅ is N;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is



R₉ is heterocycle.

92. The compound according to claim 77 wherein

X₅ is N;


R₁, R₅, R₆ and R₇ are each hydrogen;

R_{8b} is absent;

Z₁ is O;

Z₂ is NH;

L is



R₉ is heterocycle wherein said heterocycle is pyridinyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkoxy, alkyl, alkylsulfonyl, 2-azabicyclo[2.2.1]hept-2-yl, 8-azabicyclo[3.2.1]oct-8-yl, 1-azepanyl, 1-azocanyl, cyano, haloalkoxy, haloalkyl, haloalkylthio, halogen, methylenedioxy, 4-morpholinyl, 2,6,-dimethyl-4-morpholinyl, phenyl, 1-piperidinyl, 4-methyl-1-piperidinyl, pyridinyl, 1-pyrrolidinyl, 4-thiomorpholinyl, and -NZ_CZ_D; and

Z_C and Z_D are independently selected from the group consisting of hydrogen and alkyl.

93. A compound according to claim 92 that is N-(1-methyl-1H-indazol-4-yl)-4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide.

94. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

95. A method of treating a disorder wherein the disorder is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a host mammal in need of such treatment

comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

96. A method of treating bladder overactivity in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

97. A method of treating urinary incontinence in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.